ISSN 1016-5169 | E-ISSN 1308-4488
pdf
Treatment of Libman-Sacks endocarditis by combination of warfarin and immunosuppressive therapy [Turk Kardiyol Dern Ars]
Turk Kardiyol Dern Ars. 2019; 47(8): 687-690 | DOI: 10.5543/tkda.2019.29213

Treatment of Libman-Sacks endocarditis by combination of warfarin and immunosuppressive therapy

Mehmet Rasih Sonsöz1, Rukiye Dilara Tekin2, Ahmet Gül2, Zehra Buğra1, Dursun Atılgan1
1Department of Cardiology, İstanbul University İstanbul Faculty of Medicine, İstanbul, Turkey
2Department of Rheumatology, İstanbul University İstanbul Faculty of Medicine, İstanbul, Turkey

Antiphospholipid syndrome (APS) is a clinical disorder that creates an increased risk of arterial or venous thrombotic events or pregnancy-associated complications and includes the presence of autoantibodies against negatively charged phospholipids. This syndrome is often associated with systemic autoimmune diseases, such as systemic lupus erythematosus (SLE). Libman-Sacks endocarditis is a form of non-bacterial thrombotic endocarditis and is infrequently seen in APS. There are few data documenting the echocardiographic response of APS valve disease to medical treatment. This is an unusual case of a young female patient with SLE and APS who had chorea and non-bacterial thrombotic aortic valve endocarditis. Echocardiography revealed that the vegetation had receded after a combination of warfarin and immunosuppressive therapy.

Keywords: Antiphospholipid syndrome, immunosuppressive therapy; Libman-Sacks endocarditis; systemic lupus erythematosus; warfarin.











Corresponding Author: Mehmet Rasih Sonsöz, Türkiye
Manuscript Language: English
×
APA
NLM
AMA
MLA
Chicago
Copied!
CITE


Journal Metrics

Journal Citation Indicator: 0.18
CiteScore: 1.1
Source Normalized Impact
per Paper:
0.22
SCImago Journal Rank: 0.348

Quick Search

Copyright © 2024 Archives of the Turkish Society of Cardiology



Kare Publishing is a subsidiary of Kare Media.